Calcium Dobesilate A drug treatment for diabetic retinopathy

Calcium Dobesilate A drug treatment for diabetic retinopathy/Calcium Dobesilate is a vasoprotective. It is the calcium salt of dobesilic acid. It is a synthetic molecule with the ability to reduce capillary permeability in the body. In Italy, the drug is sold by the pharmaceutical company OM Pharma under the trade name of Doxium in capsules containing 500 mg of the active ingredient. A drug used to reduce hemorrhage in diabetic retinopathy.

Calcium dobesilate microvessel permeability may be reduced, increasing the resistance; improved lymph circulation, reduce edema; lower blood viscosity, corrected albumin/globulin ratio, reducing the high platelet aggregation, thus preventing thrombus formation, and increase red blood cell flexibility. Also inhibit vascular permeability high active substance-induced microvascular reduce intimal injury, to improve the biosynthesis of basement membrane collagen. Further, calcium besylate has a significant effect on improving the function of microcirculation. It can enhance the activity of macrovascular and microvascular endothelial nitric oxide synthase, ROS antagonizing capillary permeability changes, thereby protecting the vessel; can inhibit macrophage activating factor, macrophage decreased and thus has an anti-adhesive inflammatory effect.

Mechanism of Action of Calcium Dobesilate

Information not available

Indications of Calcium Dobesilate

• Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.
• Effect of calcium besylate in early stages of diabetic retinopathy
• A drug used to reduce hemorrhage in diabetic retinopathy.
• Calcium besylate is indicated in states of fragility and altered capillary permeability and in diabetic retinopathy. In combination with lidocaine or with lidocaine and dexamethasone, the drug enters the composition of preparations for the therapy of hemorrhoidal disease. In association with potassium, hydrodex-sulfate enters the composition of adjuvant gels in the treatment of varicose veins

Calcium dobesilate current market position based primarily diabetic retinopathy, but as a new vascular protecting agent, can prevent and treat various diseases caused by microcirculation disorders such as:

• (1) microcirculatory disorders caused by the heart, brain, kidney disease (myocardial infarction, angina pectoris, thrombotic complications, renal arteriosclerosis);
• (2) reduce blood viscosity;
• (3) micro thrombosis prophylaxis;
• (4) `numbness of the limbs, cold hands, and feet, pain, pruritus embolism;
• (5) varicose syndrome and the like. With its chronic complications of diabetes and ischemic heart and cerebrovascular disease prevention and control research deepening, the drug has broad application prospects.

Contraindications of Calcium Dobesilate

• The drug is contraindicated in subjects with known hypersensitivity to the active ingredient or to any of the inactive ingredients contained in the pharmaceutical formulation.
• It is also contraindicated in women who are pregnant and breastfeeding.

Dosage of Calcium Dobesilate

• Calcium dobesilate is administered orally at a daily dose of 1-1.5 g (equivalent to 2-3 tablets).
• It can also be administered rectally in the case of hemorrhoidal disease.

Side Effects of Calcium Dobesilate

Most common

• During treatment, gastrointestinal disorders can be observed: dyspepsia, nausea, vomiting, diarrhea. These disorders generally regress with the simple decrease in the dose taken, or with the temporary suspension of the treatment.

Common

• Other adverse events related to hypersensitivity reactions have also been reported: among these skin rashes, skin rash, fever, arthralgia (joint pain).

Rare

• Rare cases of agranulocytosis have also been reported in medical literature The rarity of the latter adverse effect led several authors to conclude that perhaps there could have been methodological errors in risk assessments.

Important Notice

The www.rxharun.com the international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication

References